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Although reduction in seizure frequency is the most common endpoint used to assess the antiepileptic efficacy, seizure frequency
alone does not provide a complete picture of effectiveness, particularly in patients with refractory epilepsy. The aim of our study
was to assess the effects of topiramate on seizure severity and health-related quality of life (HRQL), in addition to standard
efficacy measures, in an open, multicentre, 6-month trial of patients with epilepsy uncontrolled on antiepileptic drugs other than
topiramate. Two hundred and nine patients were enrolled and received topiramate for up to 6 months (initiated at 50 mg/day
and titrated to a recommended dose of 200–400 mg/day) in addition to existing medication. The median reduction in seizure
frequency from baseline to the post-titration period was 40.9% (P< 0.0001). Patients also demonstrated a mean reduction
in the Liverpool Seizure Severity Scale (LSSS) of 5.3 (P< 0.0001), which was considered clinically significant. Statistically
significant changes in HRQL were not observed with the SF-36, a generic measure. Tolerability of antiepileptic medication
was good, with a low incidence of cognitive adverse events. The results indicate that topiramate significantly reduces seizure
severity—an important aspect of HRQL—when administered as adjunctive therapy to anticonvulsant therapy.
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INTRODUCTION
Topiramate (TOPAMAXr, JANSSEN-ORTHO Inc.)
is a novel antiepileptic drug with multiple mechanisms
of action. Its pharmacological properties include
blockade of sodium channels1, enhancement of the ac-
tivity of GABA at GABAA receptors2, and inhibition
of kainate-induced currents3. Topiramate is indicated
for adjunctive therapy in patients with epilepsy who
are not controlled on conventional therapy. Investiga-
tions of the efficacy and the safety of topiramate (200–
1000 mg/day) as adjunctive therapy were performed
initially in adults with refractory partial-onset seizures
with or without secondarily generalized seizures
in six randomized, double-blind, placebo-controlled
trials4–9. Subsequently, the efficacy and safety of
topiramate (6 mg kg−1/day) as adjunctive therapy have
been confirmed in children with refractory partial-
onset seizures with or without generalized seizures10.
Efficacy and safety have been further assessed in
adults and children with generalized seizures11 and
Lennox–Gastaut syndrome12. In addition, a pilot
study has suggested that topiramate is a promising new
agent for the treatment of infantile spasms13.
Reduction in seizure frequency is the most com-
mon endpoint used to assess the efficacy of new
treatments in epilepsy14. However, it has become
apparent that seizure frequency alone is an inadequate
measure15, 16. This is particularly the case for patients
with refractory epilepsy, for whom minimizing side
effects of medication, reducing seizure severity
and improving psychological well being, may be
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equally valuable therapeutic goals16, 17. Consequently,
alternative or additional outcome measures to seizure
frequency are required. Health-related quality of life
(HRQL) measures provide information on the effects
of therapies on physical, social and psychological well
being from the patient’s perspective. Such measures
are being used increasingly alongside traditional
measures of efficacy and safety as indicators of
therapeutic outcome in many diseases18, 19.
Since conventional clinical trials involve heavily
selected target populations and a variety of other
constraints, they provide little information on the
day-to-day use of a drug20. This article presents
the results of a multicentre, open 6-month trial of
topiramate as add-on therapy for patients with epilepsy
not satisfactorily controlled on existing treatment,
examining the effects on partial and generalized
seizures. This trial, which recruited a broad spectrum
of patients and permitted adaptable dosages, enabled
topiramate to be investigated under the conditions of
actual clinical practice. This was the first trial designed
to assess the effects of topiramate on seizure severity
and HRQL in addition to standard efficacy and safety
measures. Effects on partial and generalized seizures
were examined. Since weight gain is often an issue
with traditional antiepileptic drugs, and weight loss
has been reported with topiramate4–12, weight change
was assessed as part of the safety profile throughout
this trial.
MATERIALS AND METHODS
Patient population
The study population included 209 patients with
refractory epilepsy. Recruitment was based on eligi-
bility criteria and willingness to participate. Inclusion
criteria required patients to be at least 18 years of
age, to have been on a stable antiepileptic drug
regimen for at least 28 days prior to the baseline
visit, and to have reported at least six seizures
within the 12-week retrospective baseline period.
The principal exclusion criteria included non-epileptic
seizures, conditions that might impair a patient’s
reliable participation or safety in the trial, pregnancy
or breast feeding, and use of topiramate during the 12-
week retrospective baseline period. Written informed
consent was obtained from each patient or legal
guardian.
Study design
This open-label, non-comparative trial was performed
in over 40 centres in Canada according to Good Clin-
ical Practice and the guidelines of the International
Conference on Harmonization21. The protocol was
approved by independent ethics committees. Eligible
patients received topiramate as adjunctive therapy to
existing medication for up to 6 months. Topiramate
therapy began at 50 mg/day and patients were titrated
to an effective dose over an anticipated period of
8 weeks. The dose increases, guided by clinical out-
come, were of 50 mg/day, with increments at weekly
intervals. The recommended dose, administered as
two divided doses, was 200–400 mg/day. Concomitant
antiepileptic medication was adjusted as required
during the study, at the discretion of the investigator.
Four clinic visits were scheduled: baseline (visit 1),
and on-treatment months 1 (visit 2), 3 (visit 3) and 6
(visit 4). Patients discontinuing from the trial early
were requested to return to the clinic so that the
final assessments could be performed at termination
(visit 4).
Evaluations
Seizures were classified according to the recom-
mendations of the International League Against
Epilepsy22 as partial, generalized, or other. Baseline
assessments (visit 1) included medical history, and
seizure history including seizure frequency over the
12-week retrospective baseline period. Neurological
examination, complete blood count (CBC) including
differential counts, weight and calculation of body
mass index (BMI), and a urinary pregnancy test were
also performed.
Patients used diaries to record the date and type
of each seizure experienced during the trial. Seizure
frequency data were transcribed into the case report
form at clinic visits 2, 3 and 4. These data were used
to calculate the following efficacy outcomes relative to
the seizure frequency during the 12-week retrospective
baseline period:
(a) percentage reductions in the average monthly
(28-day) seizure rate for the last 8 weeks that
the patient was in the trial and for the entire
treatment period (from the start of titration
through to the last dose on trial);
(b) percentages of patients experiencing ≥50%
reduction in seizure frequency for the entire
trial;
(c) percentage of patients who were seizure free for
the last 8 weeks;
(d) change in seizure frequency by seizure type for
the last 8 weeks.
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Table 1: The components of the Liverpool Seizure Severity Scale.
Sub-scale No. of items Description of items
Ictal/post-ictal 12 Loss of consciousness, level of confusion, time to recovery,
injury, headaches, incontinence, lip smacking, tongue biting, overall severity
Percept scale 8 Level of perceived control, timing, clusters, aura or warning,
prevention of normal activities
For patients participating in the trial for less than
8 weeks, the data for the period that they were included
were used and standardized to a 28-day month.
Prior to treatment, patients were asked to com-
plete two questionnaires for the previous 4-week
baseline period: the Liverpool Seizure Severity Scale
(LSSS)23, which is a disease-specific measure of
seizure severity providing information on an important
aspect of HRQL; and the Short-Form 36 (SF-36)24,
which is a generic HRQL scale. Seizure severity
and HRQL were re-assessed at the end of treatment
(visit 4) using the LSSS and SF-36.
The LSSS, a 20-item patient-based scale, is divided
into two subscales: the ictal and post-ictal effects
of seizures (comprising 12 items) and the patient’s
perception of control (comprising eight items). Each
item is scored on a simple Likert1–4 scale. The
higher the total score, the greater the seizure severity.
The scale has recently been adapted to accommodate
individuals who may experience more than one seizure
type25. This modified, validated scale was used in
the present trial, and patients with more than one
seizure type were requested to complete a scale for
their most severe seizures (major seizures) and another
for their least severe seizures (minor seizures). The
components of the LSSS are presented in Table 1.
The SF-36 comprises 36 items across eight separate
health domains including one item measuring health
transition, which encompass the three dimensions
of mental health, physical health and perception of
general health24. Patients’ scores on each domain
are linearly transformed to a 0–100 scale, with
100 indicating the most favourable and 0 the least
favourable health state. The components of the SF-
36 are presented in Table 2. A reduction in SF-36
score of 5 points or more is statistically significant26,
and a reduction of 10 points or more implies
clinically significant improvement. At the final visit,
investigators rated their treatment satisfaction using
a global evaluation of improvement on a Likert1–5
scale (worse, none, minimal, moderate or marked).
Similarly, at this visit patients rated their overall
assessment of the trial medication on a Likert1–4 scale
(poor, fair, good or excellent).
Table 2: The components of the Short-Form 36.
Domain No. of items
Physical functioning 10
Role functioning—physical 4
Bodily pain 2
General health 5
Vitality 4
Social functioning 2
Role functioning—emotional 3
Mental health 5
Reported health transition 1
Safety
Adverse events (AEs), concomitant medications,
weight (including calculation of BMI) and CBC
(including differential counts) were recorded at clinic
visits 2, 3 and 4. Investigators were requested to assess
the association of AEs with the use of topiramate.
Neurological examination was performed at baseline
and at visit 4. Reasons for early termination were
recorded.
Statistical methods
The population sample size of approximately 200
patients was based on the intention to perform
exploratory subgroup analyses (e.g. by baseline
seizure type). This sample size was considered ample
to examine the effects of topiramate on overall
seizure frequency. Based on clinical experience, it
was estimated that 50 patients would be required to
demonstrate a mean (±standard deviation) decrease
from baseline in monthly seizure rate of 40% (±60)
(P = 0.05; 99.6% power).
Three populations were used in the analyses. The
safety population included all patients who took
at least one dose of trial medication. The intent-
to-treat (ITT) population included patients in the
safety population who provided seizure data at the
baseline visit and at least one other clinic visit. It
was anticipated that there would be a stable dose
period during the trial. However, due to significant
dose variations during the trial, it was not possible to
establish a stable dose maintenance period. A post-hoc
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Table 3: Seizure frequency outcomes across all seizure types.
Population
ITT (n = 201) MITT (n = 160)
Outcome Time frame % P-value % P-value
Median % reduction in seizure frequency Last 8 weeks 40.9 <0.0001 50.0 <0.0001
Median % reduction in seizure frequency Entire trial 29.2 0.0095 41.6 <0.0001
Percentage of patients with ≥50% Last 8 weeks 44.3 51.9
reduction in seizure frequency
Percentage of patients with ≥50% Entire trial 36.8 43.1
reduction in seizure frequency
Percentage of patients seizure free Last 8 weeks 10.0 11.3
decision was made to examine data over 16 weeks,
comprising an 8-week ‘titration’ period and an 8-week
‘post-titration’ treatment period. The modified-intent-
to-treat (MITT) population included the ITT patients
who contributed at least 16 weeks of dose and seizure
information.
The Wilcoxon sign rank test was used to detect
statistically significant changes from baseline for
the following outcomes: percentage reduction in the
number of seizures (overall and within each seizure
type); change from baseline in the LSSS; change
from baseline in the SF-36 (overall, eight domains
and three health dimensions). Two-sided P-values of
≤0.05 were considered to be statistically significant.
Sample size estimations were performed based on a
mean (+/− standard deviation) percent decrease from
baseline in the frequency of monthly seizures of 40
(+/−60). Changes in weight and BMI from baseline
to visit 4 were assessed using the paired t-test. The
relationship between baseline BMI and change in BMI
to visit 4 was explored using a regression analysis.
RESULTS
Patients
The trial examined patients who were not well con-
trolled on existing therapy and whose daily lives were,
therefore, affected substantially by their epilepsy. The
mean age of the study population was 37 years
(range 18–78 years), 92% of patients were Caucasian
and 58% were female. Patients had suffered from
epilepsy for an average of approximately 23 years
(range 1–60 years). Over 70% of the patients were
receiving two or more anticonvulsant medications at
baseline. The most common concomitant medication
was carbamazepine, which was used by 30% of the
patients.
A total of 209 patients were enrolled in the trial.
The safety population comprised 205 patients; four
patients were excluded from the safety analyses
because of inadequate documentation of their epilepsy
and the study parameters. Four patients in the safety
population could not be evaluated for efficacy because
of missing seizure diary information, and the ITT (per-
protocol) population therefore comprised 201 patients.
The MITT population (patients receiving at least
16 weeks of treatment) comprised 160 patients.
During the retrospective 12-week baseline period
for patients in the ITT population the number
of patients reporting seizures were: simple partial
(SP) 60, complex partial (CP) 135 and secondarily
generalized (SG) 63. Fewer patients reported ex-
periencing primary generalized seizures during this
baseline period. The number of patients in the ITT
population who reported generalized seizures were:
absence (A) 12, atypical absence (AA) 4, atonic
(AT) 2, myclonic (MY) 7, tonic (T) 2 and tonic–clonic
(TC) 14.
The final dose and mean dose for the last 8 weeks
of the trial were reasonably consistent within each
population (293 vs. 289 mg/day, respectively, for ITT;
324 vs. 321 mg/day, respectively, for MITT). Patients
in the ITT and MITT populations received treatment
with trial medication for a mean of 151 and 175 days,
respectively.
Efficacy and health-related quality of life
Efficacy and HRQL data were derived for both the
ITT and MITT populations. Since the ITT and MITT
results were very similar, and because the ITT is
the more rigorous study population, the following
description of results focuses on the ITT population
alone. However, data for both the ITT and MITT is
presented in the tables and figures.
The seizure frequency outcomes are summarized in
Table 3. The median reduction in monthly seizure rate
from the baseline period to the last 8 weeks was 40.9%
(P< 0.0001), and for the entire treatment period
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was 29.2% (P = 0.0095), in the ITT population
(Table 3). Overall, 44.3% of patients experienced a
≥50% reduction in seizure frequency from baseline
to the last 8 weeks, compared with 36.8% of patients
when assessed from baseline for the entire treatment
period. Table 4 shows the pattern of reduction in
seizure frequency, where (as stated above) 44.3% of
patients experienced a ≥50% reduction, and 28.4%
of patients experienced a ≥75% reduction. Freedom
from seizures (100% reduction) during the last eight
weeks in the trial was experienced by 10.0% of
patients (Table 4).
Table 4: Pattern of reduction in seizure frequency from
baseline to last 8 weeks.
Population
Percentage reduction ITT (n = 201) MITT (n = 160)
in seizure frequency n % n %
100 20 10.0 18 11.3
≥75 57 28.4 52 32.5
≥50 89 44.3 83 51.9
0 142 70.6 122 76.3
Table 5 presents the numbers of patients experienc-
ing seizures and the reduction in seizure frequency
from baseline to the last 8 weeks by seizure type. For
the more common types of seizures (CP, SG and SP),
substantial percentage reductions in monthly seizure
rate were reported from the baseline period to the last
8 weeks: CP P = 0.0002, SG and SP P< 0.0001.
Marked reductions in TC (P = 0.0002) and A (P =
0.0205) seizures were also reported, but these analyses
should be regarded with caution because of the small
numbers of patients reporting these types of seizure
(Table 5).
The mean reduction in the LSSS score between
baseline and end of treatment was 5.3 points
for the ITT population (Table 6). This difference
was statistically (P< 0.0001) and also considered
clinically significant. The SF-36 showed reductions
in the mean scores for the mental health dimension
(P = 0.0301) and the mental health domain (P =
0.0025) between baseline and the end of treatment for
the ITT population (Table 7). Despite the statistical
significance of these SF-36 findings, the differences
were of insufficient magnitude to be considered
clinically significant.
Observations were also made regarding any po-
tential relationship between LSSS and SF-36 scores,
and seizure response and continuation/discontinuation
status. The reduction in LSSS score by seizure
response is shown in Fig. 1. Patients with a 75% or
greater reduction in seizure frequency also reported a
considerable reduction in the severity of their seizures
(P = 0.0002). Of all patients, those who continued
to the end of the trial achieved a greater reduction in
LSSS score and a lower mean LSSS score at endpoint
than patients who did not complete treatment (Fig. 2).
Of all patients, those who continued to the end of
the trial achieved a greater improvement in SF-36
domain scores at the final clinic visit than patients who
discontinued treatment prematurely (Fig. 3).
At the final clinic visit, investigators rated im-
provement in condition as marked or moderate for
53.7% of the ITT population and 65.0% of the MITT
population. Similarly, 54.7% of the ITT patients and
65.0% of the MITT patients rated the trial medication
as good or excellent.
Safety
Across the entire safety population (n = 205), there
were 1119 reports of AEs by 186 patients during
the 6-month trial period. A total of 757 (67.6%)
of the AEs were considered to be drug related. Of
these drug-related AEs, fatigue (6.0%), somnolence
(5.3%) and headache (4.2%) were the most frequently
occurring. The majority of the drug-related AEs, 713
(94%), were mild or moderate in severity; 44 were
of marked severity, the most frequent being dizziness
and somnolence, which were each reported by three
patients. Only one patient developed a kidney stone.
There were 18 serious AEs reported by a total of
12 patients; none were considered by the investigators
to be drug related.
Fifty-four patients (26.3%) were withdrawn from
the trial prematurely. Of these, 28 patients (13.7%)
reporting a total of 66 AEs withdrew because of AEs.
Anorexia, memory difficulties, nervousness, paraes-
thesia and increased number or intensity of seizure
were the most frequent reasons for early termination.
Contrary to previous studies of topiramate which have
suggested that cognitive problems lead to high drop-
out rates5, 27, 28, in the present trial, only nine patients
(4.4%) withdrew because of cognitive AEs, which
accounted for a small proportion of the AEs which
led to withdrawal, and included memory difficulties
(6.1%), concentration difficulties (4.5%), cognitive
problems (3.0%), confusion (3.0%), and amnesia
(1.5%). Other reasons for withdrawal from the trial
included poor seizure control (4.4%), investigator’s
decision (2.4%), patient’s choice (2.0%), protocol
violation (1.0%) and loss to follow up (0.5%).
A consistent statistically significant decrease in
bodyweight was seen during the trial (P< 0.0001).
The mean weight loss over the course of the study
was approximately 3.5 kg. These findings were
reflected in the BMI values. Regression analysis
indicated that higher baseline BMI was associated
with a greater reduction in BMI from baseline to the
final visit (P = 0.0001); however, firm conclusions
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Table 5: Change in seizure frequency from baseline to the last 8 weeks by seizure type.
ITT population MITT population
No. Median Wilcoxon No. Median Wilcoxon
Seizure type of patients % reduction P-value of patients % reduction P-value
Partial seizures
Simple partial (SP) 60 70.58 < 0.0001 45 71.15 < 0.0001
Complex partial (CP) 135 38.89 0.0002 106 52.50 < 0.0001
Secondarily generalized (SG) 63 96.25 < 0.0001 51 91.67 < 0.0001
Primary generalized
Absence (A) 12 91.06 0.0205 10 91.06 0.0430
Atypical absence (AA) 4 28.53 0.6250 4 28.53 0.6250
Atonic (AT) 2 −537.50 1.0000 2 −537.50 1.0000
Myclonic (MY) 7 100.0 0.5781 6 100.0 1.0000
Tonic (T) 2 46.00 1.0000 2 46.00 1.0000
Tonic–clonic (TC) 14 100.0 0.0002 12 100.0 0.0010
Unclassified (UC) 2 100.0 0.5000 1 100.0 1.0000
cannot be drawn because the analysis was post-
hoc and exploratory, the study population was large,
and the slope of the regression line was not steep.
Investigators were asked to record any clinically
significant laboratory findings which emerged during
the trial and were asked to report any clinically
significant haematological findings during the trial
as an AE. Only one case of reduced white blood
cell count (2.4 × 109 L−1) was reported as an AE
and this was classified as being of mild severity
and not related to treatment with topiramate. No
clinically significant changes were reported at the final
neurological examination.
Table 6: Liverpool Seizure Severity Scale score (baseline vs.
end of treatment).
Population and Standard No. of
stage of trial Mean deviation patients P-value
ITT:
Baseline 23.1 7.6 182
End of treatment 17.8 10.0 180 <0.0001
MITT:
Baseline 23.2 7.8 155
End of treatment 17.5 10.3 153 <0.0001
DISCUSSION
This open, multicentre trial was designed to provide
a better understanding of subjects with refractory
epilepsy in a standard care setting. Past studies
of patients with epilepsy have been criticized for
focusing on a narrow spectrum of patients29, which
can lead to an unexpectedly high proportion of patients
with an unfavourable outcome. Therefore, the present
study was performed at over 40 centres under actual
clinical practice conditions, and included a broad
spectrum of patients experiencing a range of seizure
types. Subjects who, for at least 28 days prior to the
start of the study, were uncontrolled by existing stable
antiepileptic therapy were included. During the trial,
the dose of existing concomitant antiepileptic therapy
could be adjusted at the discretion of the investigator,
akin to normal clinical practice.
The patients in the present trial were severely
affected by their epilepsy, as reflected in the number
of concomitant anticonvulsant medications in use and
the poor control of their condition. However, despite
this, patients responded well to treatment. The seizure
response and safety data in this trial are consistent with
those obtained in other clinical trials with topiramate.
In six previous multicentre, randomized, double-blind,
placebo-controlled trials using doses between 200
and 1000 mg/day4–9, 44% of patients responded to
adjunctive topiramate treatment with at least a 50%
reduction in seizure rate. In the present trial, 44% of
patients in the ITT population and 52% of patients
in the MITT population experienced at least a 50%
reduction in seizure rate from the baseline period to
the last 8 weeks in the trial. When assessed over
the entire treatment period, 37% of patients in the
ITT population and 43% of patients in the MITT
population had at least a 50% reduction in seizure
rate. Topiramate was generally well tolerated, with
the most common AEs being related to the central
nervous system. As in previous trials11, most AEs in
the present trial were mild or moderate in severity.
There have been reports of worsening of seizures
after treatment with some antiepileptic drugs, partic-
ularly after initial use30, 31. However, topiramate has
been shown to be an effective adjunctive therapy that
does not cause a worsening of seizures and is well
tolerated by patients11. In the present trial, which
included patients with both partial and generalized
seizures, there was no deterioration in the frequency of
any seizure type following treatment with topiramate,
apart from an increase in the frequency of atonic
seizures which was of questionable significance as
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Table 7: SF-36 score (baseline vs. end of treatment).
ITT population MITT population
Mean Mean end of No. of patients Mean Mean end of No. of patients
baseline treatment (end of baseline treatment (end of
Category score (SD) score (SD) treatment) P-value score (SD) score (SD) treatment) P-value
Domain
Physical functioning 81.0 (23.1) 78.2 (25.3) 185 0.5736 80.7 (23.1) 78.4 (26.3) 156 0.8752
Role functioning— 59.7 (39.4) 59.5 (42.7) 186 0.9553 60.2 (39.9) 65.3 (41.2) 157 0.1548
physical
Bodily pain 68.6 (27.2) 72.6 (27.6) 185 0.1035 68.6 (27.2) 74.3 (26.9) 157 0.0154
General health 62.8 (23.0) 63.3 (21.0) 183 0.7485 63.1 (23.6) 65.2 (21.1) 154 0.3622
Vitality 52.0 (20.6) 49.5 (22.5) 183 0.2814 51.6 (21.2) 52.6 (21.8) 155 0.4753
Social functioning 68.7 (23.1) 65.7 (27.5) 186 0.2347 69.1 (23.4) 70.0 (26.7) 157 0.6633
Role functioning— 66.2 (40.2) 60.7 (43.5) 185 0.0811 66.2 (40.5) 65.8 (41.5) 157 0.9871
emotional
Mental health 65.9 (20.4) 60.8 (22.2) 183 0.0025 65.9 (21.2) 62.6 (22.0) 155 0.0620
Dimension
Mental health 66.9 (23.6) 62.4 (26.6) 186 0.0301 67.0 (24.2) 66.2 (25.6) 157 0.6451
General health 57.4 (19.5) 56.3 (18.5) 185 0.4580 57.3 (19.9) 58.7 (18.3) 156 0.4132
0
5
10
15
20
25
100% (free)
75-99%
50-74%
0-49%
<0% (worse)
100% (free)
75-99%
50-74%
0-49%
<0% (worse)
0
5
10
15
20
25
ITT population MITT population
R
ed
uc
tio
n 
in
 L
SS
S 
sc
or
e
R
ed
uc
tio
n 
in
 L
SS
S 
sc
or
e
Seizure response Seizure response
Fig. 1: Reduction in Liverpool Seizure Severity Scale score by seizure response.
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it involved just two patients. The majority of inves-
tigators and patients provided positive assessments
of the trial medication. Overall, topiramate led to a
reduced seizure frequency and seizure severity without
compromising patients’ perceived health status, as
assessed by the SF-36.
The LSSS is a valid and reliable measure of seizure
severity designed for use in patients with epilepsy23,
and was developed as part of a HRQL model17. In
the present trial, statistically significant reductions in
seizure severity, an important aspect of HRQL, were
observed between baseline and end of treatment (P<
0.0001). These improvements in LSSS score were
also considered to be of clinical significance, since a
reduction in score of more than 5 points was obtained.
In the present study, the improvement observed was
far greater than reported previously in a similar study
of lamotrigine which employed the same criteria for
measuring HRQL32.
Post-hoc exploratory analyses showed that only
patients experiencing a reduction in seizure frequency
of 75% or more also reported a notable reduction
in seizure severity (by LSSS score). Similar but
less robust findings were reported for lamotrigine
as add-on therapy in partial epilepsy, where simple
correlation and multiple-regression analysis indicated
that effects on seizure frequency, seizure severity, and
psychological well being were independent of each
other32. Thus, the reduction in seizure severity may
be considered an additional, independent effect of
treatment.
In epilepsy, the SF-36 has been used as a valid and
reliable health status measure in its own right33, 34, and
as the generic core measure for two epilepsy-specific
measures, the Epilepsy Surgery Inventory (ESI-55)35
and the Quality of Life in Epilepsy Inventory (QOLIE-
89)19. HRQL data obtained using the SF-36 have
been collected for over 5000 patients with epilepsy
across Europe34. Side effects of therapy and poor
control of seizures contribute to poor HRQL in
patients with epilepsy as was reported by patients
at the baseline of the present trial. In the UK,
SF-36 scores have been found to be lower in all
domains for patients with epilepsy compared with the
general population, and in all but three domains (role
functioning—physical, vitality and general health)
compared with a population of patients with some
other long-standing illness, such as clinical depression
and type 2 diabetes26, 33. In the present study, the
SF-36 results for the ITT and MITT populations
differed slightly. Reductions between baseline and end
of treatment were observed in the SF-36 scores for
the mental health domain and mental health dimension
for the ITT population. For the MITT population,
there was improvement between baseline and end of
treatment for the bodily pain domain. However, due
to the generic nature of the tool, all these changes
in SF-36 scores were small and were not considered
clinically significant. Further research work is required
to confirm any treatment-related effects on HRQL.
In the present trial, patients received the recom-
mended starting dose of topiramate and were titrated
to an effective dose over an 8-week period, where
possible. Tolerability was good and only 14% of
patients discontinued because of AEs during the
entire 6-month treatment period. Approximately half
of these patients discontinued during the initial 8-
week period. Recent clinical experience suggests
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that low initial doses, gradual titration and the
use of topiramate as monotherapy can improve
tolerability20, 36, 37. To even further minimize adverse
cognitive events, a starting dose of 25 mg/day is often
advised, with weekly increases in the daily dose of
25 mg38. While the incidence of AEs tends to be
highest during titration, many resolve with continued
topiramate treatment36. Some antiepileptic drugs are
known to cause significant weight gain39, 40. However,
in the present study of topiramate as adjunctive
therapy, patients experienced on average a 3.5 kg
weight loss.
Since this was not a randomized, controlled,
clinical trial, and statistical analyses were intra-group
analyses, caution is needed in the interpretation of the
results. Some patients may have reported benefits after
topiramate treatment, although these improvements
might have resulted from better care as a result
of participating in a clinical trial or period effects.
However, the improvements in seizure frequency were
consistent with the results of controlled trials with
topiramate4–9. Many patients (64%), including some
who did not achieve a significant reduction in seizure
frequency, continued with topiramate therapy beyond
the 6-month treatment period of the trial. This suggests
that there may have been some additional clinical
benefits. Reduction in seizure frequency and severity
and improvement in perceptions of health may have
contributed to patients deciding to continue with
treatment. Since the patients involved in this trial
were refractory to treatment, care should be taken
in the interpretation of the data and extrapolation to
individuals who are more responsive to antiepileptic
drugs.
In conclusion, the adjunctive use of topiramate in
a broad spectrum of patients was associated with a
significant reduction in seizure frequency and severity,
without appearing to compromise patients’ perceived
health status. At least 10% of patients were seizure
free during the last 8 weeks of the trial. Topiramate
was well tolerated, with a low incidence of cognitive
AEs, no serious idiosyncratic reactions and a low
drop-out rate. The majority of investigators and
patients rated the medication well, and 64% of patients
chose to continue with topiramate therapy after the
trial. There was a statistically significant decrease in
bodyweight during the trial. Randomized clinical trials
are currently in progress to further examine the HRQL
changes associated with topiramate.
ACKNOWLEDGEMENTS
We thank the investigators and co-ordinators of the
Top-Can-2 Study Group for their involvement in
this trial. The Top-Can-2 Study Group comprised
the following: Dr E. Andermann, Dr F. Ander-
mann, Dr S. Mercho, Dr R. Arts, Ms S. Stylings,
Dr W. Blume, Ms J. De Pace, Dr J. Bruni, Dr P. Carlen,
Ms N. Politzer, Ms S. Jones, Dr S.K. Cheung,
Mrs K. Judd, Dr J. Chu, Mrs E. Chu, Mr G. Ferland,
Dr H. Desai, Ms D. Merritt, Dr R. Desbiens,
Dr F. Dominique, Dr N. Giard, Dr A. Guber-
man, Mrs M. Couture, Dr D. Halle´, Dr K.J. Ho,
Dr I. Heinrichs, Mrs E. Heinrichs, Dr M. Javidan,
Ms F. Moghaddam, Dr M. Jones, Ms D. Abbott,
Dr J. Lachapelle, Ms N. Lachance, Ms L. Roy-
Huneault, Dr M.A. Lee, Mrs M. Robertson, Dr R. Lo,
Dr J. Maher, Ms A. Gousseau, Dr G. Moddel,
Dr L. Muresan, Ms D. O’Neil, Dr W. Murphy,
Dr C. Nair, Ms E. Abrook, Dr G. Patry, Dr N. Pillay,
Ms A. Huggard, Dr M. Sadler, Mrs J. Thompson,
Ms M. Bennett, Dr J.M. Saint-Hilaire, Ms M.P. Dube´,
Dr M. Sammaritano, Dr J. Schneiderman, Ms L. Aro,
Dr D. Selchen, Dr D. Silverberg, Dr E. Starreveld,
Mrs J. Popowich, Dr M. Thibault, Dr P. Tovich,
Mrs P. Tovich, Dr M. Veilleux, Dr F. Veloso,
Ms M. Reid, Dr S. Wiebe, Ms D. Mahar, Dr A. Wilson,
Dr T. Winder, Ms S. Spenceley and Dr M. Winger.
REFERENCES
1. Coulter, D. A., Sombati, S. and Lorenzo, R. Selective effects
of topiramate on sustained repetitive firing and spontaneous
bursting in cultured hippocampal neurons. Epilepsia 1993; 34
(Suppl. 2): 123.
2. White, H. S., Brown, S. D., Skeen, G. A. and
Twyman, R. E. The investigational anticonvulsant
topiramate potentiates GABA-evoked currents in mouse
cortical neurons. Epilepsia 1995; 36 (Suppl. 4): 34.
3. Severt, L., Coulter, D. A., Sombati, S. and
De Lorenzo, R. J. J. Topiramate selectively blocks kainate
currents in cultured hippocampal neurons. Epilepsia 1995; 36
(Suppl. 4): 38.
4. Faught, E., Wilder, B. J., Ramsay, R. E. et al. Topiramate
placebo-controlled dose-ranging trial in refractory partial
epilepsy using 200-, 400-, and 600-mg daily dosages.
Topiramate YD study group. Neurology 1996; 46: 1684–1690.
5. Privitera, M., Fincham, R., Penry, J. et al. Topiramate
placebo-controlled dose-ranging trial in refractory partial
epilepsy using 600-, 800-, and 1,000-mg daily dosages.
Topiramate YE study group. Neurology 1996; 46: 1678–1683.
6. Sharief, M., Viteri, C., Ben-Menachem, E. et al. Double-
blind, placebo-controlled study of topiramate in patients
with refractory partial epilepsy. Epilepsy Research 1996; 25:
217–224.
7. Tassinari, C. A., Michelucci, R., Chauvel, P. et al. Double-
blind, placebo-controlled trial of topiramate (600 mg daily) for
the treatment of refractory partial epilepsy. Epilepsia 1996; 37:
763–768.
8. Ben-Menachem, E., Henriksen, O., Dam, M. et al. Double-
blind, placebo-controlled trial of topiramate as add-on therapy
in patients with refractory partial seizures. Epilepsia 1996; 37:
539–543.
9. Rosenfeld, W., Abou-Khalil, B., Reife, R. et al. Placebo-
controlled trial of topiramate as adjunctive therapy to carba-
mazepine or phenytoin for partial-onset epilepsy. Epilepsia
1996; 37 (Suppl. 5): 153.
Effects of adjunctive topiramate on seizure severity and quality of life 15
10. Elterman, R. D., Glauser, T. A., Wyllie, E. et al. A double-
blind, randomized trial of topiramate as adjunctive therapy
for partial-onset seizures in children. Neurology 1999; 52:
1338–1344.
11. Biton, V., Montouris, G. D., Ritter, F. et al. A randomized,
placebo-controlled study of topiramate in primary generalized
tonic–clonic seizures. Neurology 1999; 52: 1330–1337.
12. Sachdeo, R. C., Glauser, T. A., Ritter, F. et al. A double-blind,
randomized trial of topiramate in Lennox–Gastaut syndrome.
Neurology 1999; 52: 1882–1887.
13. Glauser, T. A., Clark, P. O. and Strawsburg, R. A pilot study
of topiramate in the treatment of infantile spasms. Epilepsia
1998; 39: 1324–1328.
14. Marson, A. G., Kadir, Z. A., Hutton, J. L. and Chad-
wick, D. W. The new antiepileptic drugs: a systematic review
of their efficacy and tolerability. Epilepsia 1997; 38: 859–880.
15. Smith, D. F., Baker, G. A., Jacoby, A. and Chad-
wick, D. W. The contribution of the measurement of seizure
severity to quality of life research. Quality of Life Research
1995; 4: 143–158.
16. Walker, M. C. and Sander, J. W. Difficulties in extrapolating
from clinical trial data to clinical practice: the case of
antiepileptic drugs. Neurology 1997; 49: 333–337.
17. Baker, G. A., Smith, D. F., Dewey, M., Jacoby, A. and
Chadwick, D. W. The initial development of a health-related
quality of life model as an outcome measure in epilepsy.
Epilepsy Research 1993; 16: 65–81.
18. Wiklund, I. Quality of life and regulatory issues. Scandinavian
Journal of Gastroenterology 1996; 31 (Suppl. 221): 37–38.
19. Devinsky, O., Vickrey, B. G., Perrine, K. et al. Development
of the quality of life in epilepsy inventory. Epilepsia 1995; 36:
1089–1104.
20. Sander, J. W. A. S. Practical aspects of the use of topiramate
in patients with epilepsy. Epilepsia 1997; 38 (Suppl. 11):
S56–S58.
21. International Conference on Harmonisation Topic E6. Guide-
line for Good Clinical Practice. Step 5, Consolidated Guide-
line, 1 May 1996. Final approval 17 July 1996.
22. Commission on classification and terminology of the interna-
tional league against epilepsy, proposal for revised clinical and
electroencephalographic classification of epileptic seizures.
Epilepsia 1981; 22: 489–501.
23. Baker, G. A., Smith, D. F., Dewey, M., Morrow, J.,
Crawford, P. M. and Chadwick, D. W. The development of
a seizure severity scale as an outcome measure in epilepsy.
Epilepsy Research 1991; 8: 245–251.
24. Ware, J. E. and Sherbourne, C. D. The MOS 36-item short-
form health survey (SF-36). I. Conceptual framework and item
selection. Medical Care 1992; 30: 473–483.
25. Baker, G. A., Smith, D. F., Jacoby, A., Hayes, J. A. and
Chadwick, D. W. Liverpool seizure severity scale revisited.
Seizure 1998; 7: 201–206.
26. Ware, J. E., with Snow, K. K., Kosinski, M. and Gan-
dek, B. Validity-norm-based interpretation. In: SF-36 Health
Survey. Manual and Interpretation Guide. Boston, Mas-
sachusetts, The Health Institute, New England Medical Centre,
1993: Chapter. 10.
27. Langtry, H. D., Gillis, J. C. and Davis, R. Topiramate.
A review of its pharmacodynamic and pharmacokinetic
properties and clinical efficacy in the management of epilepsy.
Drugs 1997; 54: 752–773.
28. Dooley, J. M., Camfield, P. R., Smith, E., Langevin, P. and Ro-
nen, G. Topiramate in intractable childhood onset epilepsy—
a cautionary note. Canadian Journal of Neurological Science
1999; 26: 271–273.
29. Grouse, L. D. Hidden bias in research design. JAMA 1980;
243: 1365.
30. Perucca, E., Gram, L., Avanzini, G. and Dulac, O. Antiepilep-
tic drugs as a cause of worsening seizures. Epilepsia 1998; 39:
5–17.
31. Elger, C. E., Bauer, J., Scherrmann, J. and Widman, G. Ag-
gravation of focal epileptic seizures by antiepileptic drugs.
Epilepsia 1998; 39 (Suppl. 3): S15–S18.
32. Smith, D., Baker, G., Davies, G., Dewey, M. and Chad-
wick, D. W. Outcomes of add-on treatment with lamotrigine
in partial epilepsy. Epilepsia 1993; 34: 312–322.
33. Baker, G. A., Jacoby, A., Buck, D., Stalgis, C. and
Monnet, D. Quality of life of people with epilepsy: a
European study. Epilepsia 1997; 38: 353–362.
34. Jacoby, A., Baker, G. A., Steen, N. and Buck, D. The SF-
36 as a health status measure for epilepsy: a psychometric
assessment. Quality of Life Research 1999; 8: 351–364.
35. Vickrey, B. G., Hayes, R. D., Graber, J. et al. A health-related
quality of life instrument for patients evaluated for epilepsy
surgery. Medical Care 1992; 30: 299–319.
36. Sachdeo, R. C. Topiramate: clinical profile in epilepsy.
Clinical Pharmacokinetics 1998; 34: 335–346.
37. Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H.,
Loiseau, P. and Perucca, E. Progress report on new antiepilep-
tic drugs: a summary of the fourth Eilat conference (EILAT
IV). Epilepsy Research 1999; 34: 1–41.
38. Mattson, R. H. Medical management of epilepsy in adults.
Neurology 1998; 51 (Suppl. 4): S15–S20.
39. Dinesen, H., Gram, L., Andersen, T. et al. Weight gain during
treatment with valproate. Acta Neurologica Scandinavica
1984; 70: 65–69.
40. Easter, D., O’Bryan-Tear, C. G. and Verity, C. Weight gain
with valproate or carbamazepine—a reappraisal. Seizure 1997;
6: 121–125.
